TrialCancer2025

Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort.

Sun Young Rha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.